Curaleaf Holdings, Inc. CURLF

Curaleaf publicly bid to acquire Aurora Cannabis in Aug 2026 after private talks stalled. Aurora says Curaleaf mischaracterized dialogue and remains focused on its short- to mid-term plan; Curaleaf contends the private approach failed and went public with a stock-and-cash offer valued at $4 per Aurora share. Aurora rejected the bid, arguing it undervalues the company, notes Aurora is debt-free while Curaleaf carries about $1 billion in debt, and says shareholders would own 7.7% of a combined entity but have only 3.2% of voting rights. Curaleaf’s moves have grown acrimonious, including an attempt to block Aurora’s at-the-money ATM stock sale via the Alberta Securities Commission. Aurora says the ATM predates the bid and benefits shareholders when strategic. The tender runs through Dec 1; even if the deal fails, a price pullback is possible. Some investors are advised to watch and consider diversified ETFs. Hostile bid and related financing moves could meaningfully alter CURLF's and ACB's strategic paths and investor sentiment.

Curaleaf Holdings, TSX:CURA, has been added to the FTSE Canada All Cap Index, boosting its visibility in Canadian benchmarks as it expands its US footprint. The cannabis operator is relocating and opening dispensaries across Connecticut, Pennsylvania, and Florida to strengthen positions in core markets while pursuing a larger, more vertically integrated platform with R&D and international ambitions. Simply Wall St flags three risk signals, including earnings pressure and a lack of near-term profitability, and warns that high compliance costs and potential shareholder dilution remain meaningful headwinds. The company argues that consolidation amid price compression in the US could improve efficiency, market share, and long-term profitability, while critics caution that optimism hinges on execution. Curaleaf is valued around CA$4.4 billion and faces competition from peers like Trulieve and Green Thumb. FTSE Canada All Cap inclusion may boost liquidity and exposure while expansion targets core markets, but earnings pressure and high costs keep profitability uncertain.

Aurora Cannabis asked the Alberta Securities Commission to require Curaleaf to fix deficiencies in its hostile bid circular: missing pro forma financials for the combined company, a legally required French-language notice in Quebec, and a bid that closes before the full 105-day deposit period. Aurora argues this makes the offer not a permitted bid under its rights plan, potentially triggering the poison pill if Curaleaf buys more than 20%. Curaleaf countered that it will extend expiration by seven hours, could provide pro forma financials if Aurora opens its books, and says notices were published in English and French. The offer remains 0.3463 Curaleaf shares plus $0.75 cash per Aurora share (implied $4.00, capped at $5.00), mostly stock, dragging Aurora holders into the combined company. The ASC now must decide; Curaleaf will extend expiry to 11:59 p.m.; bid expires Dec. 1. Regulatory hurdles and ongoing timing disputes could materially affect deal structure and investor sentiment for CURLF.

Aurora Cannabis filed an application with the Alberta Securities Commission seeking an order to address deficiencies Aurora says exist in Curaleaf's hostile bid Circular and to require Curaleaf to comply with securities laws. The company identifies missing pro forma financial statements showing the combined entity's condition, incomplete or improper timing of the minimum deposit period, and the absence of a French-language notice in Quebec. Curaleaf has refused to remedy these issues, according to Aurora, which argues the deficiencies could deprive shareholders of critical information and time to decide. The filing also contends Curaleaf's 105-day deposit period would disqualify the bid as a "permitted bid" under Aurora's Rights Plan, potentially triggering protective provisions if Curaleaf crosses 20% ownership. Aurora's board recommended shareholders reject the bid and withdraw any tendered shares. ASC intervention could delay or modify Curaleaf's bid terms and timing, affecting investor sentiment and execution risk.

Curaleaf Holdings has been added to the FTSE Canada All Cap Index, effective after the close on September 18, 2026, marking the company's second major Canadian benchmark inclusion after joining the S&P/TSX Composite in 2025. CEO Boris Jordan says the move expands liquidity and investor access, exposing Curaleaf to passive and active Canadian funds and broadening its investor base in U.S. cannabis. The FTSE Canada All Cap Index tracks large-, mid-, and small-cap Canadian-listed firms. Curaleaf is listed on the TSX as CURA and on the OTCQX as CURLF. The news release reiterates forward-looking statements and refers readers to regulatory filings for risk factors. Index inclusion generally boosts liquidity and institutional demand, moderately influencing trading and valuation.

Curaleaf launches hostile bid to acquire Aurora Cannabis in push for sector consolidation. Hostile bid to acquire Aurora marks major strategic expansion that could significantly shift Curaleaf market position and investor outlook.

Curaleaf urges Aurora Cannabis shareholders to tender shares to its takeover offer. Takeover bid for Aurora Cannabis marks a major strategic expansion for Curaleaf.

Curaleaf Holdings sent a letter to Aurora Cannabis shareholders outlining a proposal tied to a potential corporate transaction between the two companies. Direct outreach to Aurora shareholders indicates a major strategic initiative with potential to reshape Curaleaf's competitive scale and market position.

Curaleaf Holdings sends letter to Aurora shareholders. Direct outreach to Aurora shareholders signals potential strategic move with moderate effects on Curaleaf positioning.

Curaleaf asks regulators to freeze Aurora’s stock sales during ongoing hostile bid. Hostile bid with regulatory freeze request represents major strategic move likely to shift market dynamics and investor sentiment for Curaleaf.

Curaleaf filed an application with the Alberta Securities Commission to halt Aurora's ATM share issuances while Curaleaf's offer to buy all Aurora shares remains outstanding, arguing the program is an abusive defensive tactic that dilutes shareholders, raises the offer cost, and hinders acceptance. The filing says Aurora has issued about 2.81 million shares at an average US$3.04 since Curaleaf showed interest, boosting the total offer cost by more than US$11 million and diluting Aurora holders by roughly 10.8% since February 2026 (about 4.9% over that period). Aurora has described its balance sheet as debt-free with roughly C$149 million in cash. Curaleaf seeks an immediate halt to further ATM issuances and an expedited ASC hearing to protect Aurora shareholders' ability to consider the premium offer. The firm notes where to access the offer documents on Curaleaf's site, SEDAR+, and EDGAR. Halting ATM issuances could materially affect deal dynamics and Aurora shareholder value.

Curaleaf Holdings could be 28% undervalued amid unfolding disputes over Aurora share sales. Share sale disputes and valuation signals may moderately shift Curaleaf investor sentiment and near-term stock moves.

Curaleaf Holdings submitted an application to the Alberta Securities Commission seeking to halt Aurora's at-the-market share program during a pending offer. Curaleaf's regulatory filing targets a competitor's financing tool in the context of a pending offer and may produce moderate short-term effects on sector positioning.

Aurora continues criticizing Curaleaf amid escalating hostile takeover bid that could reshape ownership and control of the company. Hostile bid creates major strategic uncertainty that can alter ownership, operations and investor views of Curaleaf.

Curaleaf reaffirms its offer to shareholders as the best path to value creation in direct response to Aurora's circular. Reaffirmation of a major offer amid competing circular signals strategic moves that could alter ownership structure and long-term trajectory.

Aurora Cannabis urges shareholders to reject Curaleaf's hostile bid, claiming the offer is inadequate, undervalues Aurora and endangers shareholder value plus future upside. Hostile takeover bid by Curaleaf targets major expansion that could substantially shift its market position and investor outlook.

Aurora Cannabis urges shareholders to reject Curaleaf's hostile bid, calling the offer inadequate, undervaluing Aurora, and threatening shareholder value plus future upside. Hostile bid attempt marks major strategic expansion move with potential to substantially shift Curaleaf's scale, market position, and investor outlook.

Curaleaf reaffirms its offer as the best path to value creation for shareholders in direct response to Aurora circular. Reaffirmation of offer amid competitor circular may moderately shift market sentiment and strategic positioning.

Curaleaf Holdings launches hostile takeover bid for Aurora Cannabis, prompting questions on whether Aurora stock is a buy. Hostile takeover bid marks major strategic expansion that could reshape Curaleaf's market position and trajectory.

Curaleaf rejects Aurora defense measures and reiterates $4 premium offer in ongoing acquisition bid. Rejection of Aurora defense and reiteration of $4 premium signals aggressive acquisition push likely to reshape Curaleaf competitive position and investor sentiment.

Aurora counters Curaleaf's hostile takeover bid in a direct response. Hostile bid defense can trigger ownership shifts and alter Curaleaf's strategic path.

Curaleaf Holdings launches official hostile takeover bid for Aurora Cannabis. Hostile bid for Aurora marks major strategic expansion move by Curaleaf in cannabis sector.

Curaleaf Holdings launches a takeover bid to acquire Aurora Cannabis and invites Aurora shareholders to tender their shares to the offer. Takeover bid marks a major strategic expansion that could substantially reshape Curaleaf's market position and operations.

Curaleaf Holdings launches takeover bid to acquire Aurora Cannabis and invites Aurora shareholders to tender shares. Takeover bid marks major strategic expansion that could substantially increase Curaleaf market share and alter competitive position.

Curaleaf Holdings is evaluating an acquisition of Aurora Cannabis that could consolidate market share in the cannabis industry while posing integration and debt risks. Potential Aurora Cannabis acquisition represents a major strategic consolidation that would alter Curaleaf's scale and competitive position.

Curaleaf Holdings announces takeover bid for Aurora Cannabis. Takeover bid signals major strategic expansion with potential to alter market position and performance.

Curaleaf launches hostile takeover attempt on ACB, prompting questions over potential ACB stock purchases during the bid. Hostile takeover attempt marks major strategic expansion that could substantially shift Curaleaf's market position and trajectory.

Curaleaf Holdings launches a hostile $270 million takeover bid for Aurora. Hostile acquisition attempt marks major strategic expansion that could reshape competitive position and growth path.

Curaleaf Holdings proposes acquiring Aurora Cannabis for $4.00 per share. Proposed acquisition of Aurora Cannabis represents a major strategic move that could significantly expand Curaleaf's scale and market position.

Aurora Cannabis Inc. responds to Curaleaf Holdings, Inc.'s press release announcing intention to launch an unsolicited takeover bid. Unsolicited takeover bid signals major strategic move with potential to significantly alter Curaleaf's trajectory and market position.